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Biomarkers of Environmental
Benzene Exposure
C. Weisel, R. Yu, A. Roy, and P. Georgopoulos
Environmental and Occupational Health Sciences Institute,
UMDNJ-Robert Wood Johnson Medical School, Piscataway, NewJersey
Environmental exposures to benzene result in increases in body burden that are reflected in
various biomarkers of exposure, including benzene in exhaled breath, benzene in blood and
urinary trans-trans-muconic acid and S-phenylmercapturic acid. A review of the literature indicates
that these biomarkers can be used to distinguish populations with different levels of exposure
(such as smokers from nonsmokers and occupationally exposed from environmentally exposed
populations) and to determine differences in metabolism. Biomarkers in humans have shown that
the percentage of benzene metabolized by the ring-opening pathway is greater at environmental
exposures than that at higher occupational exposures, a trend similar to that found in animal
studies. This suggests that the dose-response curve is nonlinear; that potential different
metabolic mechanisms exist at high and low doses; and that the validity of a linear extrapolation
of adverse effects measured at high doses to a population exposed to lower, environmental
levels of benzene is uncertain. Time-series measurements of the biomarker, exhaled breath,
were used to evaluate a physiologically based pharmacokinetic (PBPK) model. Biases were
identified between the PBPK model predictions and experimental data that were adequately
described using an empirical compartmental model. It is suggested that a mapping of the PBPK
model to a compartmental model can be done to optimize the parameters in the PBPK model to
provide a future framework for developing a population physiologically based pharmacokinetic
model. Environ Health Perspect 104(Suppl 6):1141-1146 (1996)
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Introduction
Benzene is present in the environment,
primarily the air, because ofemissions from
automobiles, the petrochemical industry,
and combustion processes. It has been
demonstrated that tobacco smoke is a
primary contributor to indoor air levels of
benzene, thereby increasing personal expo-
sure to benzene above that from ambient
levels (1,2). Benzene is metabolized by the
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body by two different pathways, with a
number of metabolites excreted in the
urine. The complete metabolism of ben-
zene takes hours following its entry into the
body via an inhalation exposure route; thus,
benzene is present in the blood and expired
in the breath for extended time periods. A
series of potential biological markers of
exposure therefore exists for benzene,
including expired benzene, blood benzene,
and urinary metabolites ofeach pathway.
ExhaledBreath Concentrations
The continuous environmental exposures to
benzene have resulted in benzene being
detectable in the expired breath (2) in the
general population. A relationship between
benzene exposure as measured by personal
monitors and the breath concentration was
identified during the Total Exposure
Assessment Methodology (TEAM) study,
indicating that breath concentration
reflects inhalation exposure (3). Differences
between the benzene breath concentrations
ofsmokers (21 pg/m3) and nonsmokers (7.8
pg/m3) were observed in workers without
occupational benzene exposure, confirming
smoking as an exposure source ofbenzene
and expired benzene as a biomarker ofthat
exposure (4). A similar relationship between
the breath concentration of smokers (14
jig/m3) and nonsmokers (2 pg/m3) was
detected during the TEAM study (2). An
association between benzene breath concen-
tration and the time spent driving an auto-
mobile shortly before the breath sample was
taken was identified using stepwise regres-
sion analysis with an r2 = 0.55 at an x= 0.5
level (5). The interior ofan automobile has
been demonstrated to have higher benzene
concentrations than other microenviron-
ments such as outdoors and residences
without smokers (6-8). Changes in the
benzene breath concentration with time fol-
lowing distinct environmental exposures to
benzene have been empirically modeled
using the sum of two exponential expres-
sions, suggesting that a minimum of two
compartments exist within the body with
different biological resident times, a rapid
exchange region with resident times of
minutes such as the blood, and more
slowly exchanging regions with biological
residence times oftens ofminutes to hours
such as in rapidly perfused tissue (9,10).
Higher level exposures, such as those that
occur in occupational settings, have identi-
fied a third, more slowly exchanging, com-
partment, presumably fatty tissue, that
uptakes and releases benzene with biologi-
cal resident times oftens ofhours (11).
Blood Concentrations
The general population has a log-normal
distribution of blood concentrations of
benzene; this has been measured in the
National Health and Nutrition Examina-
tion Survey (NHANES) project, with the
volatile organic compound (including ben-
zene) blood concentrations associated with
recent exposures (12). As was identified for
breath, blood benzene concentrations of
smokers were elevated compared to those
of nonsmokers (13). A correlation was
identified with blood and breath levels for
benzene consistent with the expected equi-
librium between these two bodily fluids
(13). A correlation between occupational
exposures and blood benzene concentra-
tions has been identified (14).
UrnaryMetabolites
Urinary phenol. trans-trans-muconic acid
and S-phenylmercapturic acid (PMA) are
the two excreted metabolites that have
been used most as biomarkers of benzene
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exposure in occupational studies. The
utility ofurinary phenol as a biomarker of
benzene exposure is limited to inhalation
exposures at air concentrations exceeding 3
mg/m3 and has been found to be propor-
tional to benzene concentrations at expo-
sures as high as 620 mg/m3 (15-17).
Additional sources of urinary phenol due
to diets and ingestion of medicine (18)
have precluded its use as a biomarker of
environmental benzene exposures. Urinary
S-phenylmercapturic acid is a metabolite
of the ring hydroxylation pathway ofben-
zene. It was found to be increased in a
dose-response fashion to benzene in the
urine ofcoke production workers, in a sim-
ilar manner as urinary phenol, and to be
higher in the postshift urine compared to
prework urine of two workers exposed to
1.1 and 0.15 ppm benzene when no
discernable differences in the urinary phe-
nol levels were detectable (19). This sug-
gested that urinary S-phenylmercapturic
acid is a more sensitive biomarker ofben-
zene exposure than urinary phenol. Urinary
S-phenylmercapturic acid was used to evalu-
ate benzene exposure ofcar mechanics who
were exposed to a mean concentration of 1
ppm, with a stronger correlation between
exposure and than determined for urinary
trans-trans-muconic acid (20) and workers
at a chemical plant, who had a geometric
mean benzene exposure level of 0.1 ppm,
as well as smokers and nonsmokers, with a
statistically significant between the urinary
excretion of both S-phenylmercapturic
acid and urinary trans-trans-muconic acid
with the benzene exposure (21). Urinary
S-phenylmercapturic acid appears to be a
specific and sensitive biomarker ofbenzene,
whose only apparent source is the ring
hydroxylation pathway; thus it has the
potential to be a useful biomarker oflow-
level benzene exposures (22). However, it
is excreted in very low quantities (pg/g cre-
atinine) and requires a complex analytical
method to be analyzed. Urinary trans-
trans-muconic acid has been used as a bio-
marker ofsub-mg/m3 exposures (23-25),
the upper range ofenvironmental benzene
exposure; but other sources of this urinary
metabolite have been identified, such as
metabolism ofsorbic acid-a food additive
(26,27)-which makes it a nonspecific
biomarker of low-level environmental
benzene exposure. Urinary trans-trans-
muconic acid was found to be elevated in
a single individual, as was the exhaled
breath concentration, following exposure
to benzene-contaminated water (28). A
study ofsix individuals exposed to benzene
in environmental tobacco smoke (ETS)
found they also had elevated urinary trans-
trans-muconic acid compared to their uri-
nary trans-trans-muconic acid on days
without ETS exposure, but the use ofuri-
nary muconic acid as a biomarker in this
study depended upon a knowledge ofboth
the background excretion rate ofmuconic
acid and the background exposure to ben-
zene from other sources, and thus cannot be
generalized to use in the general population
for short-term exposures (29). A correlation
between urinary benzene and the time-
weighted 8-hr exposure among nonexposed,
nonsmokers, smokers, and occupationally
exposed individuals has been reported, but
the exposure levels were higher than would
occur for environmental exposures (30).
Thus urinary biomarkers ofbenzene expo-
sures currently have limited utility in estab-
lishing low-level, distinct environmental
exposures in individuals, particularly in
single urine samples.
Methodology
Research using biomarkers ofenvironmental
benzene exposure has been successful when
applied in two categories: distinguishing
chronic exposures on a population basis,
such as smokers versus nonsmokers, and
evaluating changes in a single individual
after an exposure event, provided care was
taken to establish the individual's back-
ground biomarker levels resulting from
existing chronic environmental exposures
and confounding compounds that con-
tribute to the biomarker (such as sorbic acid
to trans-trans-muconic acid). These latter
data have also been used to determine what
portion ofthe biomarker can be attributed
to the exposure event being studied. Time-
series data on changes in biomarker concen-
tration following an exposure can be used
to evaluate physiologically based pharmaco-
kinetic (PBPK) models.
BreathSamples
The analysis of low-level benzene breath
concentrations has relied on combining sev-
eral breaths (either whole or alveolar) into a
tedlar bag (3), adsorbent trap (10), or canis-
ter (31,32) to obtain sufficient quantities of
benzene to be detectable. These breath
samples have been analyzed by gas chro-
matography (GC) or gas chromatogra-
phy-mass spectrometry (GC-MS) in a
manner analogous to the analysis of air
samples. Detection capability ofsub-pg/m3
values is possible and sequential samples
can be collected during the rapidly chang-
ing benzene breath concentrations to
determine the biological half-life and
evaluation ofPBPK models.
UrinaryMeabolites
Both high-power liquid chromatography
(HPLC) and GC methods have been
developed that are sufficiently sensitive to
measure background levels oftens ofng/ml
ofurinary trans-trans-muconic acid (24,27)
The HPLC methods require a series of
preconcentration and clean-up steps, with
added specificity obtained when using a
scanning ultraviolet/visible (UV/VIS) spec-
trophotometer as the detector (29). A highly
specific and sensitive method of GC-MS
analysis has been developed using isotopi-
cally labeled trans-trans-muconic acid
obtained by feeding labeled benzene to mice
as an internal standard. A second GC
method, using flame ionization detection
(FID) has been developed (5); this method
is simpler to perform and more readily
adapted to most laboratories but is not as
specific or sensitive as the internal standard
GC-MS technique. The GC methods
require derivitization prior to the GC analy-
sis. All three approaches have been compared
in the analysis oflow-level urine samples
and provided comparable results (33).
PhysiologicallyBased
Pharmacokinetic Modeling
The PBPK model developed by Travis (34)
describing benzene was evaluated using
time-series exhaled-breath concentration
data, and the bodyweight ofthe subject was
taken into account in determining parame-
tervalues used in the model.
Results and Discussion
BreathSamples
The exhaled benzene breath concentration
during and following environmental
benzene exposure in ETS increased expo-
nentially during exposure to benzene and
then decreased in an exponential fashion
once the exposure ceased (Figure 1). The
ratio of the inspired air to the exhaled
breath concentration during the exposure
represents the absorption efficiency across
the lung-blood capillary boundary. The
absorption efficiency was greatest at the
initial part ofthe exposure and declined as
the exposure continued, reflecting a shift
in equilibrium as the benzene blood
concentration increased. An average value
of 64% has been determined for these
environmental exposures (10) that exceeds
the absorption efficiencies of 30% calcu-
lated during higher and more prolonged
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exposures of >100 mg/m3 and several
hours (35). The absorption efficiencies for
Sprague-Dawley rats and B6C3F1 mice are
31 and 50%, respectively (36). These
differences indicate that when calculating
the internal dose (the amount ofthe expo-
sure that enters the body), the exposure
250
200
150
100
50
Exposure duration
+
0 U..i&
level and duration must be (
evaluate whether a steady-st;
has been reached. Further, (
of absorption efficiency cal
high-exposure studies to er
conditions will tend to unde
inhalation dose.
a Breath
+ Breathin
° o a 0
4) 4) \V (. .* .y
Figure 1. Benzene concentration in breath as a function of time, during and postexposure (SubjE
30 min, 218 pg/m3).
100 -
90 -
80 -
70 -
60 -
50 -
40 -
30 -
20 -
10 -
PBPK model
* Data
100 -
90 -
80 -
70 -
60 -
50 -
40 -
30 -
20 -
10 -
* -1 *
50 100 150 200 250 300
Time, min
PBPK model
* Data
0 50 100 150 200 250 300
Time, min
0 50 100 150 ;
Time, min
0 50 100 150
Time, min
Figure 2. Comparison of measured exhaled breath concentrations with PBPK model-simulated pr(
considered to PBPKModel Evaluation
ate condition The series of breath concentrations meas-
extrapolation ured during and following single exposures
Eculated from reported by Yu and Weisel (10) were used
ivironmental to evaluate the PBPK benzene model as
Zrestimate the described by Travis et al. (34). A consis-
tent bias in the prediction of the breath
concentration by the PBPK model com-
pared to the experimental data following a
2-hr exposure was found (Figure 2). These
ig zone air data were adequately modeled using an
empirically based two-compartment model
assuming exponential decline (Figure 3).
The systematic deviations observed with
the PBPK model are to be expected, since a
number ofparameters in that model were
derived using interspecies extrapolation
and because the model is meant to repre-
sent the pharmacokinetics of an average
individual; furthermore, the pharmacoki-
netics of a specific individual may differ
significantly due to interindividual variabil-
ity. To expand the utility of pharmacoki-
netic modeling, it is desirable to develop a
4O ,+ population PBPK model that will provide
V estimates ofthe distribution in tissue dose
act no. 5, 8/26/93, (or other dose surrogate, such as amount
metabolized) over a population, rather
than to obtain point estimates ofdose.
One approach to developing population
PBPK models is to map a PBPK model
* Data onto a compartmental model and thereby
establish a relationship between the para-
meters in the two models (this can be
accomplished by adopting system reduc-
tion methods (37) and lumping theory
(38). The population pharmacokinetic
model can then be developed based on the
compartmental model using standard pop-
ulation pharmacokinetic software such as
the nonlinear mixed effects model (NON-
*, MEM) developed at the University of
200 250 300 California at San Francisco (39). The pop-
ulation pharmacokinetic parameters are
then mapped back into the PBPK model to
obtain a population PBPK model.
- PBPKmodel The PBPK model parameters will not * Data be uniquely determined by the compart-
mental model parameters, since the com-
partmental model is a lower-order system
having fewer parameters. Instead, the
PBPK model parameters will be specified
by a range of values and by constraints
between the parameters.
The feasibility of describing the data
with a simple two-compartment pharmaco-
* kinetic model has been demonstrated by the
200 250 300 good fit to the data obtained by that model.
Ifsuch a mapping approach is successful, it
will be possible to develop physiologically
ofiles. based population pharmacokinetic models.
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A population pharmacokinetics model
will enable probability-based risk esti-
mates rather than point estimates. This is
particularly important when risk calcula-
tion for the general population rather than
a homogeneous subpopulation in a single
setting is attempted, as there is a wide
distribution of physical and biological
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population that form heptatoxic benzene metabolite trans-
parameters in a trans-muconaldehyde (40). The percentage
ofthe benzene dose excreted as this metabo-
lite may therefore be indicative ofa poten-
iconmcAcid tial adverse health outcome. It has been
nic acid is one of reported in both mice and rats that the per-
d from the ring- centage ofthe benzene dose metabolized via
thway, that may the ring-opening pathway increases as the
dose decreases at concentrations below the
saturation value ofenzyme systems (41,42).
- 2 Compartment Ifa similar variation in the proportion of
* Data benzene metabolized by the ring-opening
pathway occurs in humans, estimates ofthe
cancer potency factor based on high-dose
animal studies and ppm occupational data,
calculated using a no-threshold model,
underestimates the risk at environmental
exposures in the tens ofparts per billion
(23,37). The percentages ofbenzene metab-
olized to and excreted as trans-trans-
muconic acid for different exposures and in
iO 200 * 250 300 different species are given in Table 1. These
results suggest that the percentage ofa dose min metabolized by the ring-opening pathway is
greater at low doses in humans and animals.
These variations in the percentage of the
- 2Compartment benzene dose excreted as different metabo- * Data lites suggest that one or more ofthe elimi-
nation pathways is nonlinear and may have
different metabolic mechanisms active at
different concentrations; therefore the use
of a linear, no-threshold model to predict
cancer risk from low-level benzene exposure
may not be valid. Further, ifthe ring-open-
ing pathway produces toxic metabolites, an
increase in their production rate as the dose
; _ decreases would lead to an underestimation
O 200 250 300 ofthe health risk at environmental exposure
min ifa no-threshold mechanism is correct.
Figure 3. Two-compartmental models of post-breath concentration and experimental data.
Table 1. Relationship between dose and proportion of benzene excreted as trans-trans-muconic acid.
Exposure/Dose Subject Exposure route Proportion Reference
0.02-0.3 pg/kg Human, 70 kg Inhalation 21% (7.2-33%) (28)
(19-159 ppb/hr)
0.01-1 mg/kg Human Inhalation 2% (43)
(7-539) ppm/hr)
0.5 mg/kg DBA/2N mice Intraperitoneal 9.8% (41)
880 mg/kg 0.4%
0.5 mg/kg C57BL/6 mice 17.6%
0.2%
1 mg/kg Mice Gavage 18% (42)
10 mg/kg 14%
1 mg/kg Rats 11%
10 mg/kg 9%
0.34-0.5 g/kg Rabbits Oral 0.45% (44)
Conclusion
Exhaled breath and urinary muconic acid
are biomarkers of environment exposure,
but each must be used within narrowly
prescribed conditions that define back-
ground levels in the individuals being
characterized, or to establish group differ-
ences. The amount of metabolism by the
ring-opening pathway is greater at low
exposure in humans than at high exposure,
as found in animals; thus, care is needed
when extrapolating potential health risk
from high to low dose. The benzene PBPK
model needs further evaluation using
human data; optimization of parameters by
mapping it to a compartmental model holds
promise as a step in producing a population
pharmacokinetic model.
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